ProUroCare Medical Inc. · OTC:PUMD
ProUroCare Medical — Shareholder Meeting (August 2009)
24 slides from ProUroCare Medical's shareholder meeting presentation, Aug 11, 2009
Slide 1: 2009 Annual Shareholders Meeting
2009 Annual Shareholders Meeting Proprietary Medical Imaging Technology
Slide 2: Safe-Harbor Statement
Safe-Harbor Statement Certain statements contained in this presentation are forward-looking in nature, and are based on the current beliefs of our management as well as assumptions made by and information currently available to management, including statements related to the markets for our products
Slide 3: Prostate Cancer Interest in the News
ProUroC roUrolare Prostate Cancer Interest news Should Men Get Prostate Cancer Screening? Prostate Cancer Studies May Leave Men Flummoxed By AUDREY GRAYSON ‘THE WALL STREET JOURNAL. cl ‘ABC News Medical Unit March 18,200 — FeATHLOURNAL | anRenat 28 The Man, the Gland, the Dilemmas By MELINDA BECK #%
Slide 4: Prostate Cancer Reporting
Prostate Cancer Reporting Friday, July 31, 2009 DODD HAS PROSTATE CANCER Sen. Christopher Dodd, D-Conn., said today he has prostate cancer and will undergo surgery during the August recess, the Hartford Courant reported. Dodd, who is leading the Senate Health, Education, Labor and Pensions Committee
Slide 5: Prostate Cancer Awareness Week
Prostate Cancer Awareness Week September 20 – 26, 2009 The Purpose One of the oldest and most successful coordinated cancer screening programs in history... and we have only just begun to reach the millions of people who need to hear our message. What We Do Each year the Prostate Conditions Educatio
Slide 6: Prostate Cancer Awareness Week Corporate Sponsors
Prostate Cancer Awareness Week Corporate Sponsors
Slide 7: Recent ProUroCare Awareness Coverage
Recent ProUroCare Awareness Coverage Medical Device Daily – potential benefits of ProUroScan featured on front page article CEOcast – eleven minute interview with CEO about ProUroCare Health Imaging and IT – ProUroScan System featured in story
Slide 8: The Clinical Challenges of Prostate Disease
The Clinical Challenges of Prostate Disease Physiologic Issues Slowest growing cancer in males Capsule compromise changes disease profile Treatment morbidity may be worse than disease itself Procedural Issues Large number of unnecessary biopsies ~75% of biopsies are negative Numerous repeat biopsies
Slide 9: Status of Current Detection Tools
Status of Current Detection Tools DRE is subjective and operator dependent Lesions difficult to characterize on palpation PSA is a derived result with low specificity No images or physical record produced DRE and PSA combined have 56% diagnostic value1 ¹Annals of internal Medicine, March 2007
Slide 10: ProUroScan Solution
ProUroScan Solution Creates a map/real time image of prostate Initial map serves as baseline image Physician can compare maps over time Maps can be stored electronically Image can be used to evaluate extent of mapping done on the prostate gland
Slide 11: Real-time images and output screens
During the procedure, real-time images provide guidance and feedback to ensure test is performed properly Upon completion of the procedure, the results and complete images are displayed Prostate image Prostate Elasticity Imaging Output Screens
Slide 12: Prostate Cancer Disease Continuum
Prostate Cancer Disease Continuum General Screening Urologist Assessment Urologist Treatment Active Surveillance 25-30MM PSA’s 1 million Biopsies/year 100,000 Radical Prostatectomies per year PMI Technology Position 2.7M Men with Prostate Cancer annually
Slide 13: ProUroScan Product Development
ProUroScan Product Development Cart-based system proven reliable
Slide 14: Components of ProUroScan System
Hand held transrectal probe Enclosure with computer and data acquisition unit Touch screen monitor Calibration device Keyboard Compact color printer Medical grade isolating transformer Components of ProUroScan System
Slide 15: ProUroScan Product Development
ProUroScan Product Development Cart-based system proven reliable Portable system developed and tested
Slide 16: ProUroScan Product Development
ProUroScan Product Development Cart-based system proven reliable Portable system developed and tested New low cost sensor technology planned PDA product concept defined
Slide 17: Prostate Elasticity Imaging Technology
Real-time imaging system for creating a map of the prostate 19 Prostate Elasticity Imaging Technology
Slide 18: ProUroScan Regulatory
ProUroScan Regulatory Product labeling strategy defined Guidelines provided by FDA Regulatory path defined (510k) Clinical study guidelines defined Clinical study protocol prepared Informed consent and data forms prepared
Slide 19: ProUroScan Clinical Studies
ProUroScan Clinical Studies Five clinical study sites identified/trained Forty five patients evaluated as of 8/10/09 Four patients remaining to complete study Regulatory submission drafted Submission planned for September 2009 510(k) generally reviewed within 90 days
Slide 20: ProUroScan Manufacturing
ProUroScan Manufacturing Four firms identified and evaluated Mpls firm selected to transition manufacturing Preliminary assessment of Artann procedures and documentation judged as very positive Program defined for moving product to manufacturing
Slide 21: ProUroCare Business Model
ProUroCare Business Model System placements: Early 2010 – Portable system with reusable probe: Portable system Per test charge Late 2010 – Portable system with disposable probe1: Portable system Per test charge Disposable probe 1Implemenation of a disposable probe may require FDA clearance
Slide 22: ProUroCare 2008 - 2009 Accomplishments
ProUroCare 2008 - 2009 Accomplishments Completed $3,050,000 public offering in January Exhibited at Annual AUA Meeting (May 2009) Initiated discussions with potential corporate partners Selected chairperson for scientific advisory panel Obtained consumer media exposure Completed freedom to operate a
Slide 23: Moving Forward 2009 Goals
Moving Forward 2009 Goals Obtain FDA clearance Make portable system market ready Complete laboratory evaluation of new sensors Assemble scientific advisory board Complete manufacturing transition plan Expand the current Board of Directors Close additional short term financing
Slide 24: Moving Forward 2010 Goals
Moving Forward 2010 Goals Complete clinical testing of low cost probe Complete development of disposable probe Establish distribution agreement with corporate partner Complete engineering and scale-up for contract manufacturing Evaluate requirements for a PDA-like product concept
ProUroCare Medical — Shareholder Meeting (August 2009) on 6ix